New CMS rule restricts federal reimbursement for puberty blockers, hormone therapy, and surgeries
The Trump administration has finalized a federal rule prohibiting the use of Medicaid and Children’s Health Insurance Program (CHIP) funds for gender transition-related medical treatments for individuals under 18, marking a major shift in U.S. healthcare policy for transgender youth.
The rule, issued by the Centers for Medicare & Medicaid Services (CMS), blocks federal reimbursement for puberty blockers, cross-sex hormone therapy, and gender transition surgeries when provided to minors. Officials say the policy is intended to take effect in October 2026, with full implementation expected by April 2027.
Policy Scope and Implementation
Federal funding restrictions
The rule does not yet criminalize gender-affirming care or prohibit states from allowing such treatments. However, it prevents federal Medicaid and CHIP dollars from being used to cover them.
Because Medicaid and CHIP jointly cover more than 35 million children nationwide, the change is expected to significantly affect access for low-income families, particularly in states where public funding is a primary source of coverage.
Administration Justification
Safety and medical uncertainty cited
CMS officials, including Administrator Dr. Mehmet Oz, said the decision is based on concerns about the long-term safety and effectiveness of gender transition treatments for minors.
The administration has described the procedures as “experimental” and pointed to potential risks such as impacts on fertility, bone development, and mental health outcomes.
President Donald Trump has repeatedly stated that federal healthcare programs should not finance treatments he considers medically unproven for children.
Legal and Political Challenges
Expected court battles
The rule is expected to face immediate legal challenges from civil rights groups and Democratic-led states, many of which have already sued the administration over earlier efforts to restrict federal funding for gender-affirming care.
Federal courts have previously issued temporary injunctions in related cases, and legal experts anticipate further litigation over whether CMS has authority to impose such funding restrictions under federal Medicaid law.
Financial Impact
Budget savings, significant policy impact
CMS estimates the rule will reduce federal spending by approximately $235 million over 10 years, a fraction of total Medicaid and CHIP expenditures.
Outlook
The policy is expected to intensify the national debate over transgender healthcare, parental rights, and federal authority in medical regulation, and is likely to remain a major issue in both courts and political discourse through 2026 and beyond.
